5 Best Stocks to Buy Today
Company (Ticker) | 12 Week Price Change | Forward PE | Price | Proj EPS Growth (1 Year) | Projected Sales Growth (1Y) |
---|---|---|---|---|---|
Enovis (ENOV) | -6.05% | 9.97 | $30.82 | 9.15% | 6.62% |
Nexxen International Ltd. Sponsored ADR (NEXN) | -4.93% | 9.20 | $9.80 | 17.20% | 8.65% |
Integral Ad Science Holding (IAS) | 10.58% | 26.57 | $8.96 | 47.10% | 13.38% |
Arcutis Biotherapeutics (ARQT) | 9.22% | NA | $15.43 | 60.78% | 67.83% |
Root (ROOT) | -39.69% | 25.98 | $88.13 | 105.20% | 16.36% |
*Updated on September 2, 2025.
Stock #1
Enovis (ENOV)
$30.82 USD -0.08 (-0.26%)
3-Year Stock Price Performance

Premium Research for ENOV
- Zacks Rank
Buy 2
- Style Scores
A Value A Growth B Momentum A VGM
- Market Cap:$1.77B (Mid Cap)
- Projected EPS Growth:9.15%
- Last Quarter EPS Growth: -2.47%
- Last EPS Surprise:6.76%
- Next EPS Report date:Nov. 5, 2025
Our Take:
Enovis Corporation is a medical technology company. Its range of products, services and integrated technologies fuel active lifestyles in orthopedics and beyond. Enovis Corporation, formerly known as Colfax Corporation, is based in Wilmington, DE.
Envois is a strong choice for value and growth stock investors. Enovis recently came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.62 per share a year ago.
Enovis shares have lost more than 40% since the beginning of the year versus the S&P 500's gain of nearly 8%. Still, analysts believe there is room for the stock price to grow: The current share price early this week was 69.5% below the average analyst price target.
Stock #2
Nexxen International Ltd. Sponsored ADR (NEXN)
$9.80 USD -0.23 (-2.29%)
3-Year Stock Price Performance

Premium Research for NEXN
- Zacks Rank
Buy 2
- Style Scores
A Value B Growth B Momentum A VGM
- Market Cap:$636.07M (Small Cap)
- Projected EPS Growth:17.20%
- Last Quarter EPS Growth: 69.23%
- Last EPS Surprise:52.63%
- Next EPS Report date:Nov. 21, 2025
Our Take:
Nexxen International Ltd. provides advertising technology platform with expertise in video and Connected TV. Nexxen International Ltd., formerly known as Tremor International Ltd., is based in New York.
The stock is a strong current choice for Value Investors, if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.38 early this week indicates a potential upside of 53.3%.
The mean estimate comprises eight short-term price targets with a standard deviation of $1.51. While the lowest estimate of $14.00 indicates a 39.6% increase from the current price level, the most optimistic analyst expects the stock to surge 79.5% to reach $18.00.
Stock #3
Integral Ad Science Holding (IAS)
$8.96 USD -0.03 (-0.33%)
3-Year Stock Price Performance

Premium Research for IAS
- Zacks Rank
Buy 2
- Style Scores
B Value A Growth B Momentum A VGM
- Market Cap:$1.49B (Mid Cap)
- Projected EPS Growth:47.83%
- Last Quarter EPS Growth: 40.00%
- Last EPS Surprise:75.00%
- Next EPS Report date:Nov. 11, 2025
Our Take:
Integral Ad Science Holding LLC operates as a digital advertising verification company. It operates principally in the United States, the United Kingdom, Germany, Italy, Spain, Sweden, Singapore, Australia, France, Japan, Canada, Hong Kong and Brazil. Integral Ad Science Holding LLC is based in New York.
The stock is a strong choice for growth investors. The company is expected to earn $0.34 per share for the full year, which represents a change of +47.8% from the prior year. IAS stock has had five estimates moving higher over the past month with no negative revisions. The consensus estimate has also received a boost over this time frame, increasing 32.7%.
The share price early this week was 47.39% below the average analyst price target for the stock.
Stock #4
Arcutis Biotherapeutics (ARQT)
$15.43 USD -0.09 (-0.58%)
3-Year Stock Price Performance

Premium Research for ARQT
- Zacks Rank
Buy 2
- Style Scores
D Value A Growth A Momentum B VGM
- Market Cap:$1.86B (Mid Cap)
- Projected EPS Growth:60.34%
- Last Quarter EPS Growth: 35.00%
- Last EPS Surprise:27.78%
- Next EPS Report date:Nov. 5, 2025
Our Take:
Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
The stock is currently a strong choice for Momentum and Growth Investors. Within the past quarter, the Zacks Consensus Estimate for ARQT's full-year earnings has moved 20.9% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
The share price early this week was 45.81% below the average analyst price target for the stock.
Stock #5
Root (ROOT)
$88.13 USD -4.09 (-4.44%)
3-Year Stock Price Performance

Premium Research for ROOT
- Zacks Rank
- Strong Buy 1
- Style Scores
B Value A Growth F Momentum B VGM
- Market Cap:$1.42B (Mid Cap)
- Projected EPS Growth:105.20%
- Last Quarter EPS Growth: 20.56%
- Last EPS Surprise:21.70%
- Next EPS Report date:Oct. 29, 2025
Our Take:
Based in Columbus, Ohio, Root Inc. is the parent company of Root Insurance Company. It is a technology company revolutionizing personal insurance with a pricing model.
The stock is a strong choice for growth investors. ROOT recently came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to a loss of $0.52 per share a year ago. Root, which belongs to the Zacks Insurance - Property and Casualty industry, posted revenues of $382.9 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 13.62%.
Root shares have grown more than 27% year to date. Still, analysts believe there is room for further growth: the share price early this week was 41.62% below the average analyst price target for the stock.
Methodology
The Zacks Rank is a proprietary stock-rating model that uses trends in earnings estimate revisions and earnings-per-share (EPS) surprises to classify stocks into five groups: #1 (Strong Buy), #2 (Buy), #3 (Hold), #4 (Sell) and #5 (Strong Sell). The Zacks Rank is calculated through four primary factors related to earnings estimates: analysts' consensus on earnings estimate revisions, the magnitude of revision change, the upside potential and estimate surprise (or the degree in which earnings per share deviated from the previous quarter).
Zacks builds the data from 3,000 analysts at over 150 different brokerage firms. The average yearly gain for Zacks Rank #1 (Strong Buy) stocks is +23.62% per year from January, 1988, through June 2, 2025.
Average target price is based on average short-term price targets offered by analysts who cover the respective companies. For this list, only companies in the top 50% of industries that have average daily trading volumes of 100,000 shares or more and at least five analysts covering the stock were considered. All information is current as of market open, Sept. 2, 2025.
Common Questions of New Investors
Where to Buy Stocks
To invest in stocks, you must open a brokerage account, fund the account and purchase stocks through your selected brokerage. Investors may also purchase stocks through a financial advisor or an automated robo advisor. Some publicly traded companies also offer a direct stock purchase plan, where you can purchase shares directly from the company.
Alternative Ways to Invest in Stocks
You can also invest in stock funds, such as mutual funds, index funds and exchange-traded funds, where the fund managers select the pool of stocks that follow an investing strategy. These funds may broadly cover an entire index, such as the S&P 500, or specific types of stocks, such as industries like technology and energy companies, company size such as small cap companies, or location like international companies.
How to Start Investing in Stocks Today
It’s easy to start investing by opening an online brokerage account. Opening a standard brokerage account takes about 20 minutes and you’ll need to have some personal information ready, such as your social security number and your bank details to fund your account.
You’ll need to decide whether to open a taxable account (most common), a tax-deferred retirement account such as a traditional IRA or a tax-free retirement account such as a Roth IRA, which is funded with after-tax dollars, but qualified withdrawals are tax-free. A margin account allows for borrowing to purchase stocks and is best for experienced traders.
Set goals before you begin investing – determine how much you can afford to invest and your tolerance for risk.
What to Look for When You Buy Stocks?
The goal in all equities investment is to buy low and sell high, growing your wealth over time. Researching the companies to invest in is key – what kind of product or service do they offer? How do they compare with competitors? How fast are they growing? Does the stock pay regular dividends to shareholders? Does the stock help diversify your portfolio by giving you exposure to a market segment you currently don’t hold?
Understanding fundamental analysis can help determine whether the stock has the potential for growth at its current purchase price. Factors that can help determine that include earnings per share (EPS), price-to-earnings ratio and PE growth. Technical analysis is used looking at statistical patterns to potentially predict future price moves. Some investors may look for a growth and income strategy, looking for stocks with solid revenues that pay good dividends, or a value strategy, looking if a current stock price is below what their revenue, EPS and other factors suggest.
Analysts also often look for the momentum of a stock by looking at moving averages of a stock's closing price over a 50-day, 100-day or 12-month trailing time period to determine signals whether to buy or sell a stock.